https://orcid.org/0000-0002-8701-2412
Citations (28)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (1)
Qi Cai, Geng-wei Huo, Fu-yi Zhu, Ping Yue, Dong-qi Yuan & Peng Chen. (2022) Safety and efficacy of immune checkpoint inhibitors in advanced cancer patients with autoimmune disease: A meta-analysis. Human Vaccines & Immunotherapeutics 18:7.
Read now
Read now
Articles from other publishers (27)
John C Hunting, Andrew T Faucheux, Sarah N Price, Catherine A Elko, Alexander Quattlebaum, Chance Bloomer, Eric Olson, William J Petty & Thomas W LycanJrJr. (2024) Patterns of neurological adverse events among a retrospective cohort of patients receiving immune checkpoint inhibitors. Immunotherapy 16:6, pages 381-390.
Crossref
Crossref
Wenjia Sun, Fengqi Qiu, Jing Zheng, Liangjie Fang, Jingjing Qu, Shumeng Zhang, Nan Jiang, Jianying Zhou, Xun Zeng & Jianya Zhou. (2024) CD57-positive CD8 + T cells define the response to anti-programmed cell death protein-1 immunotherapy in patients with advanced non-small cell lung cancer. npj Precision Oncology 8:1.
Crossref
Crossref
Joohyun Hong, Jiyun Lee, Sehhoon Park, Hyun‐Ae Jung, Jong‐Mu Sun, Se‐Hoon Lee, Jin Seok Ahn, Dong Hyun Sinn & Myung‐Ju Ahn. (2024) Immune checkpoint inhibitor use and the incidence of hepatitis B virus reactivation or immune‐related hepatitis in non–small cell lung cancer patients with chronic hepatitis B. Cancer.
Crossref
Crossref
Marjolein Metselaar-Albers, Irma Meijerman, Ferdi Engels, John Haanen, Jos Beijnen & Arief Lalmohamed. (2024) No detrimental association between antibiotic use and immune checkpoint inhibitor therapy: an observational cohort study comparing patients with ICI-treated and TKI-treated melanoma and NSCLC. Journal for ImmunoTherapy of Cancer 12:1, pages e008269.
Crossref
Crossref
Ea Maria Tønning Tønnesen, Magnus Stougaard, Peter Meldgaard & Johanne Lade-Keller. (2024)
Prognostic value of
KRAS
mutations,
TP53
mutations and PD-L1 expression among lung adenocarcinomas treated with immunotherapy
. Journal of Clinical Pathology 77:1, pages 54-60.
Crossref
Crossref
Pedro De Marchi, Leticia Ferro Leal, Luciane Sussuchi da Silva, Rodrigo de Oliveira Cavagna, Flavio Augusto Ferreira da Silva, Vinicius Duval da Silva, Eduardo CA da Silva, Augusto O. Saito, Vladmir C. Cordeiro de Lima & Rui Manuel Reis. (2024) Gene expression profiles (GEPs) of immuno-oncologic pathways as predictors of response to checkpoint inhibitors in advanced NSCLC. Translational Oncology 39, pages 101818.
Crossref
Crossref
Jiaxin Yin, Yuxiao Song, Yang Fu, Wang Jun, Jiazhuo Tang, Zhimin Zhang, Qibin Song & Bicheng Zhang. (2023) The efficacy of immune checkpoint inhibitors is limited in elderly NSCLC: a retrospective efficacy study and meta-analysis. Aging 15:24, pages 15025-15049.
Crossref
Crossref
Wint Yan Aung, Chung-Shien Lee, Jaclyn Morales, Husneara Rahman & Nagashree Seetharamu. (2023) Safety and Efficacy of Immune Checkpoint Inhibitors in Cancer Patients and Preexisting Autoimmune Disease: A Systematic Review and Meta-Analysis in Non–Small-Cell Lung Cancer. Clinical Lung Cancer 24:7, pages 598-612.
Crossref
Crossref
Cécile Charles, Aurélie Bardet, Nusaïbah Ibrahimi, Olivier Aromatario, Linda Cambon, Alexis Imbert, Magali Pons, Bruno Raynard, Dominique Sauveplane, Camille Pouchepadass, Cédric Baudinet, Olivier Lambotte, Aurélien Marabelle & Sarah Dauchy. (2021) Delivering adapted physical activity by videoconference to patients with fatigue under immune checkpoint inhibitors: Lessons learned from the PACTIMe-FEAS feasibility study. Journal of Telemedicine and Telecare 29:9, pages 716-724.
Crossref
Crossref
David StenehjemSolomon J. LubingaAozhou WuKeith A. Betts. (2023) Adverse event costs associated with first-line therapy for advanced non–small cell lung cancer in the United States: An analysis of clinical trials of immune checkpoint inhibitors. Journal of Managed Care & Specialty Pharmacy 29:9, pages 1054-1064.
Crossref
Crossref
Dingzhi Huang, Caicun Zhou, Gisoo Barnes, Yiyuan Ma, Songzi Li, Lin Zhan & Boxiong Tang. (2023)
The effects of tislelizumab treatment on the
health‐related
quality of life of patients with advanced non‐small cell lung cancer
. Cancer Medicine 12:16, pages 17403-17412.
Crossref
Crossref
Qian Yuan, Xiaojin Wang, Zhanglin Li, Wenzhuo Guo, Hua Cheng & Qingdong Cao. (2023) A Preliminary Study on Microbiota Characteristics of Bronchoalveolar Lavage Fluid in Patients with Pulmonary Nodules Based on Metagenomic Next-Generation Sequencing. Biomedicines 11:2, pages 631.
Crossref
Crossref
Harsha Ranganath, Amit L. Jain, Justin R. Smith, Julie Ryder, Amina Chaudry, Emily Miller, Felicia Hare, Poojitha Valasareddy, Robert S. Seitz, David R. Hout, Matthew G. Varga, Brock L. Schweitzer, Tyler J. Nielsen, Janice Mullins, Douglas T. Ross, David R. Gandara & Gregory A. Vidal. (2022) Association of a novel 27-gene immuno-oncology assay with efficacy of immune checkpoint inhibitors in advanced non-small cell lung cancer. BMC Cancer 22:1.
Crossref
Crossref
Ching-Feng Wu, Ching-Yang Wu, Chuen-Fu Lin, Yi-Wen Liu, Tzu-Chun Lin, Huei-Jyuan Liao & Geng-Ruei Chang. (2022) The anticancer effects of cyanidin 3-O-glucoside combined with 5-fluorouracil on lung large-cell carcinoma in nude mice. Biomedicine & Pharmacotherapy 151, pages 113128.
Crossref
Crossref
Xiong Qin, Ling Bi, Wenxiao Yang, Yiyun He, Yifeng Gu, Yong Yang, Yabin Gong, Yichao Wang, Xiaoxia Yan, Ling Xu, Haibo Xiao & Lijing Jiao. (2022) Dysbiosis of the Gut Microbiome Is Associated With Histopathology of Lung Cancer. Frontiers in Microbiology 13.
Crossref
Crossref
Yolanda Gomez Rodriguez, Brizaida Oliva Arguelles, Mario Riera-Romo, Jorge Fernandez-De-Cossio, Hilda Elisa Garay, Julio Fernandez Masso & Maribel Guerra Vallespi. (2022) Synergic effect of anticancer peptide CIGB-552 and Cisplatin in lung cancer models. Molecular Biology Reports 49:4, pages 3197-3212.
Crossref
Crossref
Amanda J. W. Gibson, Adrian Box, Winson Y. Cheung, Michelle L. Dean, Anifat A. Elegbede, Desiree Hao, Aliyah Pabani, Randeep Sangha & Dafydd Gwyn Bebb. (2022) Real-World Management and Outcomes of Crizotinib-Treated ROS1-Rearranged NSCLC: A Retrospective Canadian Cohort. Current Oncology 29:3, pages 1967-1982.
Crossref
Crossref
Ryotaro Ohkuma, Katsuaki Ieguchi, Makoto Watanabe, Daisuke Takayanagi, Tsubasa Goshima, Rie Onoue, Kazuyuki Hamada, Yutaro Kubota, Atsushi Horiike, Tomoyuki Ishiguro, Yuya Hirasawa, Hirotsugu Ariizumi, Junji Tsurutani, Kiyoshi Yoshimura, Mayumi Tsuji, Yuji Kiuchi, Shinichi Kobayashi, Takuya Tsunoda & Satoshi Wada. (2021) Increased Plasma Soluble PD-1 Concentration Correlates with Disease Progression in Patients with Cancer Treated with Anti-PD-1 Antibodies. Biomedicines 9:12, pages 1929.
Crossref
Crossref
Guang‐Li Zhu, Kai‐Bin Yang, Si‐Qi Tang & Liang Peng. (2021) Progression‐free survival assessed per immune‐related or conventional response criteria, which is the better surrogate endpoint for overall survival in trials of immune‐checkpoint inhibitors in lung cancer: A systematic review and meta‐analysis. Cancer Medicine 10:23, pages 8272-8287.
Crossref
Crossref
Yijun Zhang, Shumei Yan, Yan Li, Jiangbo Zhang, Yuan Luo, Pengcheng Li, Yuanzhong Yang, Yong Li, Yuhua Huang & Enhua Wang. (2021) Inhibin βA is an independent prognostic factor that promotes invasion via Hippo signaling in non‑small cell lung cancer. Molecular Medicine Reports 24:5.
Crossref
Crossref
Chongxiang Xue, Shuyue Zheng, Huijing Dong, Xingyu Lu, Xu Zhang, Jingyi Zhang, Jia Li & Huijuan Cui. (2021) Association Between Efficacy of Immune Checkpoint Inhibitors and Sex: An Updated Meta-Analysis on 21 Trials and 12,675 Non-Small Cell Lung Cancer Patients. Frontiers in Oncology 11.
Crossref
Crossref
Nicole E. Billingy, Vashti N. M. F. Tromp, Corina J. G. van den Hurk, Annemarie Becker-Commissaris & Iris Walraven. (2021) Health-Related Quality of Life and Survival in Metastasized Non-Small Cell Lung Cancer Patients with and without a Targetable Driver Mutation. Cancers 13:17, pages 4282.
Crossref
Crossref
Mohamed Eltahir, Johan Isaksson, Johanna Sofia Margareta Mattsson, Klas Kärre, Johan Botling, Martin Lord, Sara M. Mangsbo & Patrick Micke. (2021) Plasma Proteomic Analysis in Non-Small Cell Lung Cancer Patients Treated with PD-1/PD-L1 Blockade. Cancers 13:13, pages 3116.
Crossref
Crossref
Hiroshi Doi & Kozo Kuribayashi. 2021. Lung Cancer - Modern Multidisciplinary Management. Lung Cancer - Modern Multidisciplinary Management.
Manlio Mencoboni, Marcello Ceppi, Marco Bruzzone, Paola Taveggia, Alessia Cavo, Francesca Scordamaglia, Marina Gualco & Rosa Angela Filiberti. (2021) Effectiveness and Safety of Immune Checkpoint Inhibitors for Patients with Advanced Non Small-Cell Lung Cancer in Real-World: Review and Meta-Analysis. Cancers 13:6, pages 1388.
Crossref
Crossref
Roberta Affatato, Paolo Mendogni, Alessandro Del Gobbo, Stefano Ferrero, Francesca Ricci, Massimo Broggini & Lorenzo Rosso. (2020) Establishment and Characterization of Patient-Derived Xenografts (PDXs) of Different Histology from Malignant Pleural Mesothelioma Patients. Cancers 12:12, pages 3846.
Crossref
Crossref
Shumin Yuan, Xiufeng Hu, Yanqiu Zhao & Zibing Wang. (2020) Case Report: PD-1 Inhibitor Is Active in Lung Adenocarcinoma With B Cell Deficiency. Frontiers in Immunology 11.
Crossref
Crossref